Trials / Terminated
TerminatedNCT04307693
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 16 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is no clinical studies on the reduction of viral load in patients with COVID-19. This study investigate whether lopinavir/ritonavir or hydroxychloroquine reduces viral load from respiratory specimen in patients with mild COVID-19.
Detailed description
This multicenter study is an open-labelled, randomized clinical trial for 1:1:1 ratio of lopinavir/ritonavir, hydroxychloroquine, or control arm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lopinavir/ritonavir | Lopinavir / Ritonavir tablet |
| DRUG | Hydroxychloroquine sulfate | Hydroxychloroquine sulfate tablet |
Timeline
- Start date
- 2020-03-11
- Primary completion
- 2020-04-30
- Completion
- 2020-04-30
- First posted
- 2020-03-13
- Last updated
- 2020-05-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04307693. Inclusion in this directory is not an endorsement.